PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis.
Borderline tumor
Endometrioid
Endometriosis
PAX2
PAX8
PR
Seromucinous
Journal
Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849
Informations de publication
Date de publication:
06 Apr 2022
06 Apr 2022
Historique:
received:
14
08
2021
accepted:
30
03
2022
entrez:
7
4
2022
pubmed:
8
4
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Ovarian "seromucinous carcinoma" has been recently removed in 2020 5 There were no statistical differences in clinical findings between two groups. There was also no significant difference in pregnancy outcomes and recurrence between two groups. In immunohistochemical patterns, there was a statistically significant difference in PAX2 and PAX8 expression between in ovarian SMBT with or without endometriosis (P = 0.016, P < 0.001). Only a few cases of ovarian SMBT with endometriosis showed expression of PAX2 and conversely, most of the cases showed expression of PAX8. PR positivity was more prominent in ovarian SMBT with endometriosis than without endometriosis (P = 0.018), although there was no difference in positive ER expression. There were no statistical differences in WT1, CK20 and CDX2 expressions between two groups. Ovarian SMBT with endometriosis did not clinically differ from that without endometriosis. However, the molecular patterns were different between two groups and ovarian SMBT with endometriosis is close to endometrioid tumor types unlike SMBT without endometriosis. Further, a direct comparison study between seromucinous borderline tumor and endometrioid borderline tumor is needed with a gene profiling study to prove their relationship.
Sections du résumé
BACKGROUND
BACKGROUND
Ovarian "seromucinous carcinoma" has been recently removed in 2020 5
RESULTS
RESULTS
There were no statistical differences in clinical findings between two groups. There was also no significant difference in pregnancy outcomes and recurrence between two groups. In immunohistochemical patterns, there was a statistically significant difference in PAX2 and PAX8 expression between in ovarian SMBT with or without endometriosis (P = 0.016, P < 0.001). Only a few cases of ovarian SMBT with endometriosis showed expression of PAX2 and conversely, most of the cases showed expression of PAX8. PR positivity was more prominent in ovarian SMBT with endometriosis than without endometriosis (P = 0.018), although there was no difference in positive ER expression. There were no statistical differences in WT1, CK20 and CDX2 expressions between two groups.
CONCLUSIONS
CONCLUSIONS
Ovarian SMBT with endometriosis did not clinically differ from that without endometriosis. However, the molecular patterns were different between two groups and ovarian SMBT with endometriosis is close to endometrioid tumor types unlike SMBT without endometriosis. Further, a direct comparison study between seromucinous borderline tumor and endometrioid borderline tumor is needed with a gene profiling study to prove their relationship.
Identifiants
pubmed: 35387670
doi: 10.1186/s13048-022-00975-5
pii: 10.1186/s13048-022-00975-5
pmc: PMC8985320
doi:
Substances chimiques
PAX2 Transcription Factor
0
PAX2 protein, human
0
PAX8 Transcription Factor
0
PAX8 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
41Informations de copyright
© 2022. The Author(s).
Références
Int J Gynecol Pathol. 2006 Jan;25(1):83-9
pubmed: 16306790
Gynecol Oncol Rep. 2021 Mar 23;36:100756
pubmed: 33889704
Cancer. 1988 Jan 15;61(2):340-8
pubmed: 3334969
Mod Pathol. 2007 Aug;20(8):856-63
pubmed: 17529925
Jpn J Clin Oncol. 2010 Mar;40(3):208-13
pubmed: 19926591
BMC Cancer. 2020 Aug 17;20(1):769
pubmed: 32807135
Mod Pathol. 2011 Jun;24(6):751-64
pubmed: 21317881
Diagnostics (Basel). 2020 Jan 31;10(2):
pubmed: 32023964
Am J Surg Pathol. 2011 Dec;35(12):1837-47
pubmed: 21989345
Appl Immunohistochem Mol Morphol. 2011 Jul;19(4):293-9
pubmed: 21285870
PLoS Med. 2008 Dec 2;5(12):e232
pubmed: 19053170
Am J Surg Pathol. 2011 Jun;35(6):816-26
pubmed: 21552115
Am J Surg Pathol. 2008 Oct;32(10):1566-71
pubmed: 18724243
J Cutan Pathol. 2021 Oct;48(10):1246-1251
pubmed: 33934372
Int J Gynecol Pathol. 2016 Jan;35(1):78-81
pubmed: 26598986
Int J Biol Sci. 2020 Feb 24;16(8):1474-1480
pubmed: 32210734
Lancet Oncol. 2013 Aug;14(9):853-62
pubmed: 23845225
Am J Surg Pathol. 2002 Dec;26(12):1529-41
pubmed: 12459620
Int J Mol Sci. 2013 Mar 15;14(3):6090-105
pubmed: 23502471
Appl Immunohistochem Mol Morphol. 2010 Jul;18(4):323-32
pubmed: 20216401
Med J Armed Forces India. 2020 Jan;76(1):30-36
pubmed: 32020965
Front Genet. 2012 Jan 31;3:6
pubmed: 22303411
Mod Pathol. 2009 Sep;22(9):1243-50
pubmed: 19525924